🇺🇸 FDA
Patent

US 11702461

T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides

granted A61KA61K2039/605A61K2039/6056

Quick answer

US patent 11702461 (T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides) held by Cue Biopharma, Inc. expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Cue Biopharma, Inc.
Grant date
Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/605, A61K2039/6056, A61K2039/64, A61K39/12